Astex Pharmaceuticals Ltd.
http://astx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Astex Pharmaceuticals Ltd.
Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
A Standard September Ahead Thanks To Light US FDA User Fee Calendar With Few Expedited Reviews
Twelve applications with September goal dates include six novel agents but only one breakthrough designation.
Don’t Stop Relieving: Journey’s DFD-29 Trounces Oracea In Reducing Rosacea Lesions
The company posted positive topline results from the Phase III MVOR-1 and MVOR-2 trials comparing DFD-29 against Galderma’s drug in papulopustular rosacea.
Tech Transfer Roundup: MD Anderson, Replay Found Allogeneic TCR-NK Cell Therapy Play Syena
Start-up hopes to bring its first candidate, an NY-ESO-1-targeting off-the-shelf product, into the clinic in Q2. Astex and Cardiff University team up on novel therapies for neurodegenerative disease.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice